ConductScience.org, home

Library / Trial comparisons

Cangrelor Arm vs Clopidogrel Arm: Incidence of All Cause Mortality

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNoteSource
Risk in group 10.03010.02520.036wilsonClinicalTrials.gov
Risk in group 20.03140.02630.0375wilsonClinicalTrials.gov
Risk difference, group 1 minus group 2-0.00131-0.00910.00647newcombe hybrid scoreClinicalTrials.gov
Risk ratio, group 1 over group 20.9580.7451.23logClinicalTrials.gov
Odds ratio, group 1 over group 20.9570.7391.24logClinicalTrials.gov
Number needed to treat, for one fewer participant with the outcome on Cangrelor Arm than on Clopidogrel Arm765from the risk difference intervalthe interval includes no differenceClinicalTrials.gov

Groups 2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov codeSource
Group 1Cangrelor Arm
placebo capsules (to match) at PCI start + cangrelor bolus (30 mcg/kg) \& infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion) + active clopidogrel (600mg) post infusion
1163,851OG000ClinicalTrials.gov
Group 2Clopidogrel Armclopidogrel capsules (600 mg) at PCI start + placebo bolus \& infusion (to match) followed by placebo capsules post infusion1203,818OG001ClinicalTrials.gov

Outcome 5

FieldValueSource
TypeSECONDARYClinicalTrials.gov
TitleIncidence of All Cause MortalityClinicalTrials.gov
Description(excluding STEMI)ClinicalTrials.gov
Time framerandomization through 1 year after randomizationClinicalTrials.gov
PopulationmITT (excluding STEMI), based on 1 year completersClinicalTrials.gov

Trial 8

FieldValueSource
TitleA Clinical Trial to Demonstrate the Efficacy of CangrelorClinicalTrials.gov
NCT numberNCT00305162ClinicalTrials.gov
PhasesPHASE3ClinicalTrials.gov
ConditionsMyocardial Infarction (MI), Acute Coronary Syndromes (ACS)ClinicalTrials.gov
InterventionsCangrelor (P2Y12 inhibitor), clopidogrel (oral P2Y12 inhibitor), Placebo bolus & placebo infusion, Placebo capsules - end of infusion, Placebo capsules - as soon as possible after randomizationClinicalTrials.gov
Lead sponsorThe Medicines CompanyClinicalTrials.gov
Results first posted2014-04-23ClinicalTrials.gov
Results on ClinicalTrials.govhttps://clinicaltrials.gov/study/NCT00305162?tab=resultsClinicalTrials.gov

Source 4

FieldValueSource
Releasetrial-comparisons-2026-03-23-0.1.0ClinicalTrials.gov
Release manifest SHA-256f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57ClinicalTrials.gov
AACT copy2026-03-23ClinicalTrials.gov
Tables readoutcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquetClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.